LABU241213P148000
- 51.15
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Annual review | The top ten explosive stocks in the US stock market for 2024 have been released! Applovin emerges as the dark horse of the year in AI, MSTR astonishes the market with a fivefold increase for the year, and Tesla makes a comeback in the last
As of the market close on December 11, the S&P 500 Index has risen by 27% year-to-date, surpassing 6,000 points; the Nasdaq Composite Index has accumulated a rise of over 33%, reaching a milestone of 0.02 million points, exceeding market expectations.
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
BofA Restarts Coverage of 11 Large-cap Biopharmas
Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Gilead Sciences Analyst Ratings
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Reported Sunday, Gilead's Kite Highlights New Data Showcasing Yescarta's Curative Potential In Relapsed/Refractory Large B-Cell Lymphoma At ASH 2024
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304 Trial Met Primary Endpoint Of Overall Survival...
Wells Fargo's 'Value Equity' List: VZ, GM, TGT and More
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman